Evidence map›Paper›PMID 39809945›Full record

ArticleBJC reports2025

Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma.

Takeshi Terashima, Kouki Nio, Naohiko Koshikawa, Makoto Ueno, Tadashi Toyama, Masaki Miyazawa, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa, Noriho Iida and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Kouki NioDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Naohiko KoshikawaSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Tadashi ToyamaDepartment of Nephrology, Kanazawa University Hospital, Kanazawa, Japan.
Masaki MiyazawaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Tomoyuki HayashiDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Akihiro SekiDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Hidetoshi NakagawaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Noriho IidaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Shinya YamadaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Hajime TakatoriDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Tetsuro ShimakamiDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Toru YoshimuraResearch and Development, Abbott Japan LLC, Matsudo, Japan.
Eisaku YoshidaResearch and Development, Abbott Japan LLC, Matsudo, Japan.
Masatoshi NakagawaSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.
Motoharu SeikiFaculty of Medicine, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University, Kanazawa, Japan.
Taro YamashitaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan. taroy62m@staff.kanazawa-u.ac.jp.

Funding

JSPS KAKENHI Grant JP18ck0106425, JP19ck0106425, JP20ck0106425, JP21ck0106662h0001, JP21ck0106662h0002, and JP21ck0106662h0003
6 · The paper itself

Abstract

backgroundThe identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of laminin γ2 monomer (LG2m) as a biomarker in PDAC.

methodsThis study included two cohorts. Cohort 1 included 142 PDAC patients, 55 patients with intraductal papillary mucinous neoplasm (IPMN), and 46 healthy individuals. Cohort 2 included 518 PDAC patients. The medical records of patients were reviewed. Cut-off levels for LG2m were determined by receiver operating characteristic analysis.

resultsIn Cohort 1, serum LG2m levels were significantly higher in PDAC patients compared with healthy individuals (P < 0.001) and IPMN patients (P < 0.001). Comparing PDAC patients and health individuals, the optimal cut-off level of LG2m was 9.55 pg/mL and the sensitivity, specificity, and area under the curve were 0.89, 0.87, and 0.88, respectively. High sensitivity of LG2m in PDAC patients were confirmed in Cohort 2. The sensitivity and specificity of LG2m was higher than that of CEA and CA19-9. In patients treated with resection or chemotherapy, high serum LG2m level indicated a significantly shorter survival (P = 0.042 and P < 0.001, respectively).

conclusionsLG2m may be a useful diagnostic and prognostic marker for PDAC.

Identifiers

PMID39809945
PMCPMC11733115

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.